Gilead Sciences and Nurix Therapeutics, Inc., have announced a global strategic collaboration to discover, dev...
Zydus’ Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received the final approval from the ...
Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharm...
Sosei Group Corporation and its strategic alliance partner Pfizer announce that a new clinical candidate from their mult...
CStone Pharmaceuticals, on 9 June 2019, announced its global clinical collaboration with China focus with Baye...
Rykindo® (LY03004), Luye Pharma's innovative, independently developed Extended-Release Microspheres f...
Sihuan Pharmaceutical Holdings Group Ltd., the largest cardio-cerebral vascular (CCV) drug manufacturer in China's&...
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduces a novel drug comb...
Gilead Sciences, Inc. has recently announced that with effect from 1 May 2019, Vemlidy (tenofovir alafenamide, TAF)...
ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary ...
Roche has declared that Emicizumab (Hemlibra®) has been approved in India for Hemophilia A with factor VIII in...
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. The co...
Takeda Pharmaceutical Company Limited announced that the European Medicines Agency (EMA) has accepted a Marketing Author...
Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced it has r...
StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, recently announced the s...
HitGen has announced that the company has entered into a research collaboration with Almirall to identify novel small mo...
BioInvent International AB, focused on the discovery and development of novel and first-in-class immuno-regulatory antib...
Roche announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with mod...
